IEQ Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

IEQ Capital’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,222	Closed	-$77.4K	–	1014
2023 Q4	$77.4K	Hold	7,222	–	–	﹤0.01%	891
2023 Q3	$43.3K	Hold	7,222	–	–	﹤0.01%	921
2023 Q2	$49.8K	Hold	7,222	–	–	﹤0.01%	879
2023 Q1	$113K	Hold	7,222	–	–	﹤0.01%	850
2022 Q4	$144K	Hold	7,222	–	–	﹤0.01%	754
2022 Q3	$129K	Hold	7,222	–	–	﹤0.01%	791
2022 Q2	$160K	Hold	7,222	–	–	﹤0.01%	745
2022 Q1	$201K	Buy	7,222 +3,611	+100%	+$131K	﹤0.01%	767
2021 Q4	$164K	Hold	3,611	–	–	﹤0.01%	704
2021 Q3	$301K	Hold	3,611	–	–	0.01%	555
2021 Q2	$343K	Hold	3,611	–	–	0.01%	436
2021 Q1	$601K	Hold	3,611	–	–	0.02%	259
2020 Q4	$354K	Hold	3,611	–	–	0.02%	203
2020 Q3	$123K	Hold	3,611	–	–	0.01%	378
2020 Q2	$205K	Hold	3,611	–	–	0.01%	293
2020 Q1	$212K	Buy	+3,611	New	+$269K	0.02%	331

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IEQ Capital's ONCT Position: Q1 2024 in Review

IEQ Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 7,222 shares — an estimated $77.4K sold.

IEQ Capital first reported a position in ONCT in Q1 2020 and held it in 16 quarters. The position peaked at $601K in Q1 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

IEQ Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
IEQ Capital sold 7,222 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $77.4K.
IEQ Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
IEQ Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $601K in Q1 2021.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on IEQ Capital's 13F filing for Q1 2024, filed 9 May 2024.